Trillium Asset Management LLC Purchases Shares of 88,038 Merit Medical Systems, Inc. $MMSI

Trillium Asset Management LLC purchased a new stake in Merit Medical Systems, Inc. (NASDAQ:MMSI) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 88,038 shares of the medical instruments supplier’s stock, valued at approximately $6,105,000.

Several other large investors also recently made changes to their positions in MMSI. Los Angeles Capital Management LLC acquired a new stake in shares of Merit Medical Systems during the fourth quarter worth $25,000. Torren Management LLC bought a new stake in Merit Medical Systems in the 4th quarter valued at $38,000. Covestor Ltd boosted its stake in Merit Medical Systems by 252.6% in the 4th quarter. Covestor Ltd now owns 469 shares of the medical instruments supplier’s stock worth $41,000 after purchasing an additional 336 shares during the period. Danske Bank A S acquired a new position in Merit Medical Systems in the 3rd quarter worth $42,000. Finally, Quarry LP increased its holdings in Merit Medical Systems by 185.9% during the 3rd quarter. Quarry LP now owns 526 shares of the medical instruments supplier’s stock worth $44,000 after purchasing an additional 342 shares in the last quarter. Institutional investors own 99.66% of the company’s stock.

Merit Medical Systems Stock Down 1.9%

Merit Medical Systems stock opened at $90.27 on Friday. The company has a current ratio of 4.20, a quick ratio of 2.79 and a debt-to-equity ratio of 0.44. Merit Medical Systems, Inc. has a 1-year low of $59.74 and a 1-year high of $94.75. The company has a fifty day simple moving average of $76.93 and a 200 day simple moving average of $72.44. The company has a market cap of $5.39 billion, a P/E ratio of 37.30, a price-to-earnings-growth ratio of 2.31 and a beta of 0.49.

Merit Medical Systems (NASDAQ:MMSI) last issued its quarterly earnings results on Thursday, July 30th. The medical instruments supplier reported $1.19 EPS for the quarter, topping the consensus estimate of $0.96 by $0.23. Merit Medical Systems had a net margin of 9.22% and a return on equity of 13.75%. The firm had revenue of $418.84 million for the quarter, compared to analysts’ expectations of $405.25 million. During the same period in the previous year, the firm posted $1.01 EPS. The company’s revenue for the quarter was up 9.5% on a year-over-year basis. Merit Medical Systems has set its FY 2026 guidance at 4.250-4.350 EPS. Research analysts anticipate that Merit Medical Systems, Inc. will post 3.81 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have issued reports on MMSI. Robert W. Baird set a $98.00 price target on Merit Medical Systems in a research note on Friday, July 31st. Canaccord Genuity Group upped their price objective on Merit Medical Systems from $85.00 to $94.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Wells Fargo & Company increased their price objective on Merit Medical Systems from $74.00 to $83.00 and gave the stock an “equal weight” rating in a report on Friday, July 31st. Piper Sandler lifted their target price on Merit Medical Systems from $96.00 to $106.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Finally, Bank of America boosted their target price on Merit Medical Systems from $92.00 to $97.00 and gave the company a “neutral” rating in a research note on Thursday, August 13th. Eight analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Merit Medical Systems presently has a consensus rating of “Moderate Buy” and a consensus target price of $100.00.

About Merit Medical Systems

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.